Safety and Dosing Evaluation of KITE-363 and KITE-753 in Relapsed/Refractory B-cell Lymphoma Patients

The primary objective of this clinical study is to evaluate the **safety** and appropriate **dosing** of the investigational drugs, KITE-363 and KITE-753, in participants diagnosed with **relapsed and/or refractory B-cell lymphoma**. This objective is clinically relevant as it aims to determine the optimal therapeutic dose that maximizes efficacy while minimizing adverse effects, which is crucial for improving patient outcomes in this challenging condition.

The clinical trial involves a total of **25 participants** diagnosed with **relapsed and/or refractory B-cell lymphoma**. The study population includes both male and female subjects, with an age range spanning from 18 to 65 years. Participants were selected to include a vulnerable population, although specific selection criteria are not provided. The trial does not specify any particular lifestyle considerations such as diet or physical activity. The general health status of the participants is not detailed, and the sponsor has not provided information on key inclusion or exclusion criteria.

The clinical trial is designed to evaluate the **safety** and dosing of investigational drugs KITE-363 and KITE-753 in participants diagnosed with **relapsed and/or refractory B-cell lymphoma**. This study is structured as a Phase 1 trial, which is typically the initial phase in clinical research focused on assessing the safety profile of new treatments. The trial employs a randomized, double-blind, controlled design to ensure unbiased results and to maintain the integrity of the data collected. The estimated duration of the trial spans from December 6, 2023, to January 15, 2027, allowing for comprehensive data collection and analysis over this period.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. This visit will involve a thorough assessment of the participant's medical history and current health status. Following successful screening, participants will be enrolled in the study and will attend regular follow-up visits. These visits are scheduled to monitor the participants' response to the treatment, assess any adverse effects, and adjust dosing as necessary. The end-of-study visit will conclude the participant's involvement, during which final evaluations will be conducted to gather comprehensive data on the treatment's impact.

The expected length of participant involvement in the trial is contingent upon individual response to the treatment and the overall study timeline. Participants may be subject to early termination from the study if they experience significant adverse effects, fail to comply with study protocols, or if the study is discontinued for any reason. The trial is conducted under strict ethical guidelines and regulatory standards to ensure participant safety and the validity of the research findings.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the absence of specific details, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be included. The data does not contain any information about the experimental medication's maximum daily dose, maximum total dose, or maximum treatment period. Furthermore, there is no information regarding whether the medication is a **paediatric formulation** or an **orphan drug**. The trial's main objective and full title are also not provided in the data.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date is December 6, 2023, with an anticipated end date of January 15, 2027. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, typical Phase 1 trials often involve preliminary assessments of efficacy alongside safety evaluations. These assessments may include the use of validated scales, laboratory tests, or patient-reported outcomes to measure changes in relevant biomarkers or symptom improvement. The schedule for measuring and collecting data is typically aligned with the trial's protocol, ensuring systematic and consistent data collection throughout the study duration. The analysis of efficacy data will be conducted using appropriate statistical methods to determine the potential therapeutic effects of the investigational product.